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Background: gp340, a member of scavenger receptor cysteine rich family encoded by Deleted in Malignant Brain
Tumors 1 (DMBT1), is an important component in innate immune defense. The first scavenger receptor cysteine rich
domain (SRCR1) of gp340 has been shown to inhibit HIV-1 infection through binding to the N-terminal flank of the
V3 loop of HIV-1 gp120.
Results: Through homology modeling and docking analysis of SRCR1 to a gp120-CD4-X5 antibody complex, we
identified three loop regions containing polar or acidic residues that directly interacted with gp120. To confirm the
docking prediction, a series of over-lapping peptides covering the SRCR1 sequence were synthesized and analyzed
by gp120-peptide binding assay. Five peptides coincide with three loop regions showed the relative high binding
index. An alanine substitution scan revealed that Asp34, Asp35, Asn96 and Glu101 in two peptides with the highest
binding index are the critical residues in SRCR1 interaction with gp120.
Conclusion: We pinpointed the vital gp120-binding regions in SRCR1 and narrowed down the amino acids which
play critical roles in contacting with gp120.
Keywords: SRCR1, DMBT1, HIV-1 gp120, Automated dockingBackground
Salivary agglutinin (SAG) and lung scavenger receptor
glycoprotein (gp340) are multi-splicing products of
Deleted in Malignant Brain Tumors 1 (DMBT1), a gene
originally identified in brain tumors [1]. SAG, secreted
by salivary glands, was originally found to aggregate oral
streptococcus gordonii and streptococcus mutans, playing
important roles in dental caries [2]. Gp340 can also bind
a number of Gram-negative and Gram-positive bacteria,
including E. coli, Lactobacillus casei, Helicobacter pylori,
S. aureus, S. pneumoniae, and Haemophilus. Influenzae
[3-5]. Recently, gp340 was shown to inhibit cytoinvasion
of Salmonella enterica in intestinal epithelial cells [6]
and the infectivity of influenza A virus [7]. Previous* Correspondence: wzhw@nju.edu.cn
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reproduction in any medium, provided the orstudies showed that soluble gp340 specifically inhibited
HIV-1 infection [8,9], by interacting with the viral enve-
lope gp120 [10]. Subsequent studies identified that a
short sequence located at the N-terminal flank of the
gp120 V3 loop interacted with gp340 [11]. An N-SRCR
recombinant protein containing the first SRCR domain
and one-half of the first SID of gp340 was shown to bind
to the N-terminal flank of the V3 loop of gp120 and in-
hibit both CXCR4 and CCR5 HIV-1 isolates, exhibiting
similar properties as the parental gp340 [12]. Although
the bioactivities of gp340 as an innate immune compo-
nent have been well documented [13], the detailed
molecular mechanisms remain largely unclear. Since the
SRCR1 binds to a highly conserved region of HIV-1
gp120 [12], it is a potential candidate as an anti-viral
inhibitor.
SRCR consists of 90–110 amino acids and is divided
into Groups A and B, depending on the number of
disulfide bonds and the locations of the cysteines [13].
Group B SRCR, to which gp340 belongs, contains either
6 or 8 cysteines with cysteines at positions 1 and 4. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with positions 1 and 4 always absent. Since SRCR forms
a highly structured domain and it is likely that structural
elements are part of the gp120 binding domain, it is
imperative to determine the sequence or minimal struc-
tural domain needed for mediating gp120 binding. The
structure of Mac 2 binding protein (M2bp), a Group A
SRCR, has been determined by crystallography [14]. In the
current study, a 3-D structure of SRCR1 was constructed
through homology modeling based on the known struc-
ture of M2bp, and was docked with the published 3D
structure of gp120-CD4-X5 complex, which is a gp120
core in complex with soluble CD4 and a HIV-1 neutraliz-
ing antibody-X5 Fab fragment [15]. A probability analysis
was conducted on the multiple docking models [16] and
the gp120-contact amino acid residues on SRCR were
predicted. To verify the docking analysis, linear peptides
were synthesized according to the prediction values and
gp120-peptide binding analysis was conducted. The results
demonstrated the validity of the modeling and identified a
number of regions that were in contact with gp120. This
study provided atomic insight into the interactions between
gp120 and SRCR1, shedding light on the inhibitory mech-
anism of SRCR and laid the ground for further study on
the SRCR sequence/structures important for HIV-1 inhib-
ition and the design of new HIV-1 target drugs.
Methods
Modeling of SRCR1 domain
The structure of SRCR1 (residues 95–203 on DMBT1,
renumbered as 1–109 in this article) was built based on the
known structure of M2bp SRCR domain (PDB ID: 1BY2)
using software MODELLER9v4 [14,17-19]. Structural
refinements were accomplished by energy minimization
and molecular dynamics using software Insight II 2001
(Accelrys, San Diego, CA).Figure 1 Two reverse views of SRCR1 structure. β-strands are in cyan; t
sequence numbers of cysteine residues are indicated.Automated docking of SRCR1 to monomeric gp120-CD4-X5
complex
Docking of SRCR1 to the gp120-CD4-X5 complex (PDB
ID: 2B4C) was performed using ZDOCK3.0.1, a rigid-
body protein-protein docking software [20]. ZDOCK used
a fast Fourier transformation to search all possible binding
modes for the proteins, performing evaluation based on
shape complementarity, desolvation energy, and elec-
trostatics. The top predictions from ZDOCK were then
recomputed by RDOCK to improve the energies and eli-
minate clashes.
Peptide design, synthesis and purification
A complete set of 15-mer peptides, overlapping by 10
amino acids, was derived from SRCR1. These peptides
were numbered according to the SRCR1 sequence, P1
standing for 1–15 residues, P2 for 5–20 and so on. To
study the role of the vital amino acids for gp120 binding, a
set of peptides was introduced alanine substitutions in
corresponding residues. All peptides were synthesized and
purified by high-performance liquid chromatography
(HPLC) to >95% purity (HD Biosciences Co., Shanghai,
China). The biotin tag was labeled at the N-terminus of
the peptide.
Peptide binding assay (solid-phase ELISA)
Recombinant gp120s were purchased from Immuno
Diagnostics, Inc (Woburn, MA, USA) or from the NIH
AIDS Reagent Program (Bethesda, MD, USA). 96-well
polyvinylchloride plates (Corning, NY, USA) were coated
with 50 μl of 8ug/ml gp120 diluted in 50 mM bicarbon-
ate buffer, pH 9.6, and incubated at 4°C for 16 hours.
Unbound protein was removed by repeated washing with
20 mM Tris–HCl, pH7.4, containing 0.05% Tween-20
(washing buffer). Nonspecific sites were blocked with
200 μl 2% nonfat milk dissolved in washing buffer, at 37°Cwo α-helices are in magenta. Disulfide bridges are in yellow and the
Figure 2 Docking of SRCR1 with monomeric gp120-CD4-X5 complex. A) The structure of the docked SRCR1. SRCR1 and the gp120 core
(in blue) are shown in solid ribbon style. CD4 and X5 are represented in silk ribbon style with orange (CD4), green (X5 light chain) and grey
(X5 heavy chain), respectively; B) Electrostatic surface of SRCR1 (left) and the V3-loop of gp120 (right). The molecular surfaces of both SRCR1 and
the V3-loop of gp120 are colored according to the calculated electrostatic surface potential with negative charges in blue, neutral in white, and
positive charges in red; C) The closer view of the gp120-binding sites. The residues in SRCR1, which make contact with gp120, are shown as
sticks in grey, whereas the residues in gp120 are colored in blue; D) The docking frequency of residues 1–109 in SRCR1. Three high docking
frequency loop regions 33–36, 73–76 and 94–97 are indicated.
Chu et al. Journal of Biomedical Science 2013, 20:44 Page 3 of 7
http://www.jbiomedsci.com/content/20/1/44for 60 min. 50 μl of 30 μg/ml biotinylated peptides diluted
in washing buffer were added and allowed to bind gp120
at 37°C for 60 min. Unbound peptides were removed by
repeated washing. For competition studies, biotinylated
P19 (40 μg/ml) was mixed with increasing concentrations
of non-biotinylated P19, added to a gp120-coated plate
(8ug/ml) and incubated at 37°C for 60 min. Unbound pep-
tides were removed by repeated washing. Since P1 showed
no binding to gp120 in the previous binding analyses, it
was used as a control at the maximum concentration
(640 μg/ml). The bound peptides were detected with AP-
conjugated streptavidin (Vector, CA, USA) and PNPP
liquid substrate (Sigma, USA), and measured at 405 nm.Results and discussion
Structural modeling of SRCR1
DMBT1 SRCR1 and M2bp SRCR shared high homology
(50%) in primary sequence. The SRCR1 3D structure was
organized around a curved four-stranded β-sheet cradling
two α-helices (Figure 1). There were 4 disulfide bridges in
SRCR1: Cys33 and Cys97 forming a disulfide bridge that
linked the C-terminus of the β3 strand to the α2-helix; the
Cys46-Cys107 disulfide bridge linking the α1-helix to the
underlying β-sheet; the Cys77-Cys87 disulfide bridge cir-
cularizing the loop and containing a turn around Glu81;
and the Cys17-Cys51 disulfide bridge linking the α1-helix
to the β-turn between the β1 and β2 strands.
Figure 3 Gp120 interaction with SRCR1 peptides. A) The schematic illustration of SRCR1 sequence. Twenty overlapping 15-mer peptides
covering the complete SRCR1 sequence were designed and synthesized. These peptides were numbered according to SRCR1 sequence, P1
standing for 1–15 residues, P2 for 5–20 and so on. The peptides with highest binding index with gp120 were identified and the key binding
amino acids were marked with star; B) Recombinant gp120BaL interaction with peptides derived from SRCR1. Biotinylated peptides (30 μg/ml)
was allowed to bind immobilized gp120 (8 μg/ml) and were tested for their binding capability to gp120 with ELISA; C) Nonbiotinylated P19
competitively inhibited biotinylated P19 binding to gp120 (8 μg/ml). Biotinylated P19 (40 μg/ml) was pre-incubated with increasing
concentrations of non-biotinylated P19, added to a gp120-coated plate (8ug/ml) and incubated at 37°C for 60 min. Unbound peptides were
removed by repeated washing. Since P1 showed no binding to gp120 in previous binding assays, it was used as a control at the maximum
concentration (640 μg/ml).
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disulfide bridge Cys17–Cys51 while the corresponding
M2bp residues, Asn15 and Phe49, are in close proximity
with a Cα–Cα distance of 7.5 Å [14]. Hohenester et al.
postulated that the 1–4 disulfide bridge (Cys17–Cys51) in
group B domains (SRCR1) would link the C-terminus of
the α-helix (α1) to the A–B loop (β1-β2) and packed favor-
ably against the 3–8 bridge (Cys46–Cys107) [14]. The
disulfide bond Cys17–Cys51 was therefore inserted in the
structure according to their hypothesis (Figure 1). The
surface loop structure with a β-turn, located between β1
and β2 strands, was previously shown to be involved in







P5 VEILYRGSWGTVCDD 21-35 +4
P6 RGSWGTVCDDSWDTN 26-40 +4.5
P14 GSGPIALDDVRCSGH 66-80 +1.5
P15 ALDDVRCSGHESYLW 71-85 +2
P19 GWLSHNCGHGEDAGV 91-105 +7.5
P20 NCGHGEDAGVICSA- 96-109 +1.5Docking of SRCR1 with monomeric gp120-CD4-X5 complex
Our early study demonstrated that gp340 binding to
gp120 was significantly enhanced by the pre-treatment
of gp120 with soluble CD4 and that the 17b antibody
binding to the gp120-sCD4 complex did not abrogate
gp340 binding and vice versa [11]. We suggested that
the gp340-binding region on gp120 was occluded or par-
tially occluded on the native gp120 and sCD4 binding
induced the exposure of the region, thus allowing high
affinity interaction between gp340 and gp120 [11].
Therefore, we speculated that a gp120 in complex with
sCD4 would be a favorable model for our docking
analysis, Since the gp120-sCD4-17b structure does not
contain a V3 sequence [21], a newly published crystal
structure of a V3-containing HIV-1 gp120 core in com-
plex with sCD4 and a HIV-1 neutralizing antibody-X5
[15] was selected. X5 and 17b belong to the same class
of HIV-1 neutralizing antibodies termed CD4-induced
(CD4i) antibodies, which recognize highly conserved
epitopes exposed upon CD4 binding. The binding of the
CD4i antibodies to gp120 is typically enhanced by the
CD4 binding. To provide restrains on docking possi-
bilities, a number of factors were considered. First, the
location of the V3 loop and the surface for SRCR1
binding on the trimeric viral spike in native state, as
Figure 4 Determination of critical residues in P6 and P19 peptides. A) Alanine substitution scan of the peptides. Biotinylated peptides
(30 μg/ml) were allowed to bind immobilized gp120BaL (8 μg/ml). P6/34 means that Asp34 in P6 was substituted by alanine. It was same to other
peptides, such as P6/35, P19/96, P19/101 and P19/96/101; P1 was used as a negative control; B) The structural view of P6 and P19 in SRCR1
model. The P6 was colored in cyan and P19 was colored in purple. Asp34, Asp35, Asn96 and Glu101 residues were labeled on the regions of P6
and P19.
Chu et al. Journal of Biomedical Science 2013, 20:44 Page 5 of 7
http://www.jbiomedsci.com/content/20/1/44determined by Liu et al. [22], were used to orient the
SRCR1 structure in the docking. Second, gp340 is a
macromolecule with 14 SRCR domains in tandem order,
thus SRCR1 can only be docked to a region outside of
the plane formed by the β-sheet on the V3 loop due to
the steric hindrance. Figure 2A showed a typically
docked complex of SRCR1 and gp120-sCD4-X5. The
SRCR structure interacted with gp120 on the open face,
near the V3 loop site [11], and the N- and C-termini of
SRCR, which link the SRCR1 subunit to the rest of the
gp340, were pointed away from the gp120.
Analysis of gp120-contacting amino acids on SRCR1
The docked complex of SRCR1 and gp120-CD4-X5 was
shown in Figure 2A. Three regions with apparently high
docking frequencies were identified (Figure 2D): the sur-
face Loop1 between the β3 strand and α1-helix (Cys33
to Ser36), the surface Loop2 near the Cys77-Cys87 disul-
fide bridge (Asp73 to Arg76) and the surface Loop3 near
the α2-helix (Ser94 to Cys97). These three loops formed
a negatively charged cluster on the SRCR1 3D structure
and a number of amino acids contacted with the V3-
loop of gp120 as shown in Figure 2B. Figure 2C showed
a closer view of gp120-binding sites on SRCR1. Fre-
quently, Asp35 and Asp73 formed salt bridges with
Arg304 of gp120. Ser36 formed a Van der Waals inter-
action or a hydrogen bond with Thr320. Asp74 formed a
hydrogen bond with Tyr318 and Thr320. Arg76, the only
basic residue in the gp120-binding sites, frequently
formed a salt bridge with Glu322 of the V3 loop. Asn96
showed the highest binding frequency among contact
residues in SRCR1(Figure 2D), and always made contact
with Lys305, Arg304, Ser306 and Tyr318. Ser94 and
His95 frequently interacted with Tyr318. Docking ana-
lysis indicated that the frequency of gp120 interactionwith the residues 93–97 in SRCR1 was higher than that
of any other residues, suggesting that this region might
be the most important for the stability of the interaction.
xThe amino acid contacting frequency analysis was
consistent with published studies [11]. Earlier studies in-
dicated that the contribution of the charges of V3 resi-
dues dominated gp120 electrostatic potential [23] and a
minimal gp340-binding sequence was localized to the
V3 N-terminal flank (aa303-306), which was rich in
positively charged residues [11]. A V3 peptide containing
the residues 303–306 was found to bind both soluble
[11] and cell-associated gp340 [24], and inhibited gp120-
gp340 interaction. In addition, our model also suggested
that Phe317, Tyr318, Thr320 and Glu322 at the C-
terminus of the V3 were involved in gp120-SRCR inter-
action, though ELISA failed to show such an interaction
[11]. Cys33, Asp34, Asp35, Asp73, Asp74, Arg76, His95,
Asn96, and Cys97 were conserved in all 13 SRCRs of
gp340, indicating that they might be indispensable for
the bioactivity of gp340 and that the other SRCRs might
also bind gp120. In some SRCR domains, Ser36 and
Ser94 were replaced by Thr and Tyr, respectively, which
did not significantly change the polarity of the residues.
Therefore, we speculated that inter-molecular salt brid-
ges and polar interactions were conserved and important
for the specificity of the interaction.
Gp120 interaction with SRCR1 peptides
To validate the predictions of the docking analysis and to
characterize the gp120-binding region, a series of linear
peptides spanning SRCR1 sequence were synthesized and
analyzed for their interactions with gp120 in a solid-phase
ELISA. The sequence of SRCR1 was showed in Figure 3A
and the peptides with high binding index were identified
according to their location in the sequence of SRCR1.
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peptides interacting with gp120 and with P5, P6 and P19
showing the highest binding indexes. The sequence shared
by P5 and P6 was RGSWGTVCDD, which included the
high docking frequency residues Cys33, Asp34 and Asp35
within the Loop 1. P19, containing the high docking fre-
quency residues Asn96 and Glu101 in Loop 3, exhibited the
highest binding index. P14 and P15, with an overlapping se-
quence ALDDVRCSGH and high docking frequency resi-
dues Asp73, Asp74 and Arg76, also interacted with gp120.
The results were consistent with the computer modeling
and summarized in Table 1.
To demonstrate the specificity of the interaction,
biotinylated P19 binding to gp120 was competed with a
nonbiotinylated P19 in an ELISA. Figure 3C showed that
increasing concentrations of nonbiotinylated P19 reduced
the biotinylated P19 binding to gp120 in a dose-dependent
manner while the control P1 had no effect, suggesting that
the P19-gp120 interaction was sequence specific and not
mediated by the biotin.
To further confirm the docking frequency, we intro-
duced alanine substitutions into four residues with the
highest docking frequency in two peptides (Asp34 and
Asp35 in P6, Gln96 and Glu101 in P19), either individu-
ally or in combination. All the mutant peptides showed
reduced binding with gp120 (Figure 4A). However, the
P19 binding to gp120 was minimally affected by muta-
tions at 96 and 101, respectively, or in combination. We
think that this may reflect the discrepancy between the
modeling and the peptide-based binding assay. The
modeling was performed on a folded SRCR1 with three
surface loop regions directly interacting with gp120.
Asn96 and Glu101, both located in the interface of the
SRCR1-gp120 docking complex (seeing Figures 2B and
4B), were thus predicted to be important for protein
interaction. However, these two amino acids in P19 may
not be in the best conformation to interact with gp120
and some other amino acids that are not located in the
interface may be available in P19 to interact with gp120.
By using a serial of peptides based on a consensus SRCR
sequence, a bioactive peptide (SRCRP2) was shown to
bind streptococcal and mediated bacterial aggregation [4].
Interestingly, the sequence of SRCRP2 coincides with the
sequences of P5 and P6. Thus we hypothesized that the
same region of SRCR1 contributed to the binding of both
the bacterial and HIV-1. However, P5 and P6 didn’t show
significant inhibitory effect in an in vitro HIV-1 pseu-
dovirus inhibitory assay (data not shown). We also discov-
ered that disulfide bond-disrupted SRCR1 protein had
significantly reduced binding to gp120 (data not shown).
In view of the tightly folded SRCR domain, we speculated
that a certain conformational element is required for
SRCR1 to form high affinity interaction with gp120
and to inhibit HIV-1 infection, consistent with the currentobservations that the gp120-contacting amino acids were
distributed in the distal sequence. Based upon our model-
ing, P6 and P19 were linked with a disulfide bridge formed
by Cys33 and Cys97. Thus, distal residues (Asp34, Asp35,
Asn96 and Glu101) along the linear sequence were
brought to proximity by disulfide bonds and formed a
gp120 binding plain (Figure 4B). The structural element
required for SRCR1 to form high affinity binding with
gp120 and for inhibiting viral infection needs further in-
vestigation. The identification of the contacting amino
acid residues in the current study will facilitate our under-
standing of the structure and the design of molecular
mimicry expressing the needed conformation as a more
effective drug.
Conclusions
We performed docking analysis on gp120-SRCR1 inter-
action and made a number of predictions on the SRCR1
amino acid residues that may interact with gp120. Bind-
ing analysis using a series of synthetic peptides derived
from SRCR1 demonstrated that three high binding loop
regions of aa33-36, 73–76 and 94–97 on SRCR1 bound
gp120. The relative binding indexes were consistent with
the predictions of the docking model, suggesting that
our model is appropriate for further analysis of SRCR1-
gp120 interaction and that, by combining biochemical
approaches, the model may facilitate the designing of
new HIV-1 target drugs.
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